0.815
4.06%
0.0318
시간 외 거래:
.83
0.015
+1.84%
Lucid Diagnostics Inc 주식(LUCD)의 최신 뉴스
Lucid Diagnostics' SWOT analysis: esophageal cancer screening stock faces pivotal year - Investing.com UK
Lucid Diagnostics Announces Multiple Presentations at the Upcomi - GuruFocus.com
Lucid Diagnostics Strengthens and Expands Market Access and Dire - GuruFocus.com
LUCDLucid Diagnostics Inc. Latest Stock News & Market Updates - StockTitan
PAVMPAVmed Inc. Latest Stock News & Market Updates - StockTitan
American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer Test - StockTitan
Lucid Diagnostics to be deconsolidated from PAVmed’s financial statements - Medical Buyer
Lucid Diagnostics to be deconsolidated from PAVmed's financial statements - Seeking Alpha
PAVmed moves to deconsolidate Lucid Diagnostics - Investing.com
PAVmed’s Strategic Overhaul to Secure Nasdaq Compliance - TipRanks
PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements - StockTitan
Lucid Diagnostics (NASDAQ:LUCD) Given New $7.25 Price Target at Ascendiant Capital Markets - Defense World
Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress - StockTitan
Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress - PR Newswire
Lucid Diagnostics partners with Front Line to boost cancer detection in firefighters - Investing.com
Lucid Diagnostics partners with Front Line to boost cancer detection in firefighters - Investing.com India
Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health - Yahoo Finance
Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health - PR Newswire
Wall Street analysts’ outlook for Lucid Diagnostics Inc (LUCD) - SETE News
Stock Market Recap: Lucid Diagnostics Inc (LUCD) Concludes at 0.84, a -2.10 Surge/Decline - The Dwinnex
Lucid Diagnostics reports high accuracy in esophageal test study - Investing.com India
Behind Lucid Diagnostics Inc’s 52-Week Range: Uncovering Opportunities for Investors - The InvestChronicle
Analyzing LUCD’s current quarter earnings projections - US Post News
Lucid Diagnostics reports high accuracy in esophageal test study - Investing.com
Lucid Diagnostics reports high accuracy in esophageal test study By Investing.com - Investing.com Australia
Lucid Diagnostics reports high accuracy in esophageal test study By Investing.com - Investing.com UK
Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and Cancer - Yahoo Finance
Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and Cancer - PR Newswire
Lucid Diagnostics (NASDAQ:LUCD) Rating Reiterated by Canaccord Genuity Group - Defense World
Lucid Diagnostics Launches New Corporate Website - Longview News-Journal
PAVmed Inc (PAVM) Q2 2024 Earnings Call Transcript Highlights: R - GuruFocus.com
PAVmed’s EsoGuard revenue for Q2 2024 stands at USD 1.0M - Medical Buyer
Lucid Diagnostics (NASDAQ:LUCD) Lifted to Strong-Buy at Canaccord Genuity Group - Defense World
Cantor Fitzgerald stays bullish on Lucid Diagnostics, keeps $3 target - Investing.com
Lucid Diagnostics maintains Buy rating, $2.50 target amid growth By Investing.com - Investing.com Australia
Lucid Diagnostics’ (LUCD) Buy Rating Reaffirmed at Needham & Company LLC - Defense World
Lucid Diagnostics Inc. (NASDAQ:LUCD) Q2 2024 Earnings Call Transcript - Insider Monkey
The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal Cancer - Yahoo Finance
The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal Cancer - PR Newswire
PAVmed Provides Business Update and Second Quarter 2024 Financial Results - Marketscreener.com
PAVmed Provides Business Update and Second Quarter 2024 Financial Results - StockTitan
PAVmed Provides Business Update and Second Quarter 2024 Financial Results - PR Newswire
LUCD Stock Earnings: Lucid Diagnostics Beats EPS, Misses Revenue for Q2 2024 - MSN
Lucid Diagnostics maintains Buy rating, $2.50 target amid growth - Investing.com
Lucid Diagnostics maintains Buy rating, $2.50 target amid growth By Investing.com - Investing.com Canada
Lucid Diagnostics maintains Buy rating, $2.50 target amid growth By Investing.com - Investing.com UK
Earnings call: Lucid Diagnostics reports robust growth in Q2 2024 By Investing.com - Investing.com Australia
Earnings call: Lucid Diagnostics reports robust growth in Q2 2024 By Investing.com - Investing.com Canada
Earnings call: Lucid Diagnostics reports robust growth in Q2 2024 - Investing.com
Earnings call: Lucid Diagnostics reports robust growth in Q2 2024 By Investing.com - Investing.com UK
Lucid Diagnostics Inc. (LUCD) Q2 2024 Earnings Call Transcript - Seeking Alpha
LUCD Stock Earnings: Lucid Diagnostics Beats EPS, Misses Revenue for Q2 2024 - InvestorPlace
Lucid Diagnostics Inc. (NASDAQ:LUCD) Q2 2024 Earnings Call Transcript - MSN
Lucid Diagnostics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial Results - PR Newswire
Lucid Diagnostics Inc. (NASDAQ:LUCD) Position Boosted by Virtu Financial LLC - Defense World
Lucid Diagnostics Holds First Major Directly-Contracted EsoGuard® #CheckYourFoodTube Precancer Testing Event - PR Newswire
Lucid’s Esoguard doubles precancer detection - BioWorld Online
EsoGuard test improves esophageal precancer detection, claims Lucid - Investing.com India
Lucid Diagnostics Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing - PR Newswire
Lucid Diagnostics (LUCD) to Release Quarterly Earnings on Monday - Defense World
Lucid Diagnostics to Participate in Upcoming Investor Conferences - The Malaysian Reserve
Lucid Diagnostics to Participate in Upcoming Investor Conferences - PR Newswire
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing - Quantisnow
Lucid Diagnostics Reports Publication of Future Effective Foundational Local Coverage Determination by Medicare Administrative Contractor Noridian Healthcare Solutions - Quantisnow
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024 - Quantisnow
Financial Health Report: Lucid Diagnostics Inc (LUCD)’s Ratios Tell a Tale - The Dwinnex
PAVmed to Hold a Business Update Conference Call and Webcast on August 13, 2024 - Marketscreener.com
PAVmed to Hold a Business Update Conference Call and Webcast on August 13, 2024 - StockTitan
자본화:
|
볼륨(24시간):